According to the latest market report published by Credence Research, Inc. “Atopic Dermatitis (AD) Treatment Market – Growth, Future Prospects, and Competitive Analysis, 2017 – 2025” the global atopic dermatitis (AD) treatment market was valued at US$ 4.04 Bn in 2016, and is expected to reach US$ 7.66 Bn by 2025, expanding at a CAGR of 7.4% from 2017 to 2025.
Atopic dermatitis is also known as atopic eczema, it is a chronic inflammatory skin disease characterized by itchy skin lesions and rashes. It affects people of all ages but more common among infants and children. Risk factors for atopic dermatitis are mainly categorized as modifiable and non-modifiable. Modifiable risk factors include inhalant and food allergens, however, non-modifiable risk factors include genetics or heritability. For the purpose of the study AD treatment market is segmented on the basis of drug types such as anti-inflammatory agents, antihistamines, immunomodulators, interleukin inhibitors, topical phosphodiesterase-4 (PDE-4) inhibitors, antiviral agents, and antibiotics.
Browse the full report Atopic Dermatitis (AD) Treatment Market – Growth, Future Prospects, and Competitive Analysis, 2017 – 2025 at http://www.credenceresearch.com/report/atopic-dermatitis-ad-treatment-market
It is observed that currently, anti-inflammatory agents are major revenue generating segment as these drugs are preferably used as a first-line therapy after failure of skin care and moisturizers due to its effectiveness. Strong pipeline molecules such as ABT-494, apremilast, LY-3009104, GSK-2894512, REGN-668, GBR-830, MEDI-9929, nemolizumab, OPA-15406, PF-04965842, secukinumab, and tralokinumab are expected to show AD treatment market growth during the forecast period 2017-2025. In the base year 2016, North America dominated the global AD treatment market due to a large number of the target population, higher treatment awareness, swift adoption of novel medications, and better reimbursement policies. On the other hand, Asia Pacific will show highest AD treatment market growth during the forecast period due to increasing healthcare awareness among the general population and growing partnership of key players with the local manufacturer.
Market Competition Assessment:
Atopic dermatitis (AD) treatment market is observed to be highly competitive and comprises a large number of players. However, some major market players are LEO Pharma A/S, AbbVie Inc., Encore Dermatology Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, MedImmune (AstraZeneca), Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Valeant Pharmaceuticals Inc. and other.
By End User
- Research Labs
By Route of Administration
- Photo Therapy
- Directed Therapy
Key Market Movements:
– Factors such as an increase in the prevalence of atopic dermatitis, higher treatment compliance, growing prevalence of food allergies exacerbating atopic dermatitis and favorable reimbursement policies in some countries are driving the market growth of AD treatment worldwide.
– Due to the higher number of unmet needs, vendors in the market are focusing in developing ideal treatment, promising pipeline molecule, rising access for the treatment medication in some developing countries, increase in the incidence of atopic dermatitis would fuel the growth of AD treatment market during the forecast period.
– However, generic erosion, poor patient compliance in some countries and adverse effects associated with the use of medication is negatively impacting the growth of AD treatment market.
Browse the full report Atopic Dermatitis (AD) Treatment Market – Growth, Future Prospects and Competitive Analysis, 2017 – 2025 at http://www.credenceresearch.com/report/atopic-dermatitis-ad-treatment-market
Saline Laxatives Market: http://www.credenceresearch.com/report/saline-laxatives-market
Plant Stem Cell Market: http://www.credenceresearch.com/report/plant-stem-cell-market-for-cosmetics
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Get Weekly Updates
- Your information is safe with us
52total visits,3visits today